tetano
Editor, Senior Moderator
Lancet
. 2020 Jul 20;S0140-6736(20)31605-6.
doi: 10.1016/S0140-6736(20)31605-6. Online ahead of print.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Feng-Cai Zhu[SUP] 1 [/SUP], Xu-Hua Guan[SUP] 2 [/SUP], Yu-Hua Li[SUP] 3 [/SUP], Jian-Ying Huang[SUP] 4 [/SUP], Tao Jiang[SUP] 5 [/SUP], Li-Hua Hou[SUP] 6 [/SUP], Jing-Xin Li[SUP] 7 [/SUP], Bei-Fang Yang[SUP] 2 [/SUP], Ling Wang[SUP] 3 [/SUP], Wen-Juan Wang[SUP] 7 [/SUP], Shi-Po Wu[SUP] 6 [/SUP], Zhao Wang[SUP] 2 [/SUP], Xiao-Hong Wu[SUP] 3 [/SUP], Jun-Jie Xu[SUP] 6 [/SUP], Zhe Zhang[SUP] 6 [/SUP], Si-Yue Jia[SUP] 7 [/SUP], Bu-Sen Wang[SUP] 6 [/SUP], Yi Hu[SUP] 5 [/SUP], Jing-Jing Liu[SUP] 3 [/SUP], Jun Zhang[SUP] 6 [/SUP], Xiao-Ai Qian[SUP] 2 [/SUP], Qiong Li[SUP] 2 [/SUP], Hong-Xing Pan[SUP] 7 [/SUP], Hu-Dachuan Jiang[SUP] 7 [/SUP], Peng Deng[SUP] 2 [/SUP], Jin-Bo Gou[SUP] 8 [/SUP], Xue-Wen Wang[SUP] 9 [/SUP], Xing-Huan Wang[SUP] 10 [/SUP], Wei Chen[SUP] 11 [/SUP]
Affiliations
Abstract
Background: This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study.
Methods: This randomised, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan, China. Healthy adults aged 18 years or older, who were HIV-negative and previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-free, were eligible to participate and were randomly assigned to receive the vaccine at a dose of 1 ? 10[SUP]11[/SUP] viral particles per mL or 5 ? 10[SUP]10[/SUP] viral particles per mL, or placebo. Investigators allocated participants at a ratio of 2:1:1 to receive a single injection intramuscularly in the arm. The randomisation list (block size 4) was generated by an independent statistician. Participants, investigators, and staff undertaking laboratory analyses were masked to group allocation. The primary endpoints for immunogenicity were the geometric mean titres (GMTs) of specific ELISA antibody responses to the receptor binding domain (RBD) and neutralising antibody responses at day 28. The primary endpoint for safety evaluation was the incidence of adverse reactions within 14 days. All recruited participants who received at least one dose were included in the primary and safety analyses. This study is registered with ClinicalTrials.gov, NCT04341389.
Findings: 603 volunteers were recruited and screened for eligibility between April 11 and 16, 2020. 508 eligible participants (50% male; mean age 39?7 years, SD 12?5) consented to participate in the trial and were randomly assigned to receive the vaccine (1 ? 10[SUP]11[/SUP] viral particles n=253; 5 ? 10[SUP]10[/SUP] viral particles n=129) or placebo (n=126). In the 1 ? 10[SUP]11[/SUP] and 5 ? 10[SUP]10[/SUP] viral particles dose groups, the RBD-specific ELISA antibodies peaked at 656?5 (95% CI 575?2-749?2) and 571?0 (467?6-697?3), with seroconversion rates at 96% (95% CI 93-98) and 97% (92-99), respectively, at day 28. Both doses of the vaccine induced significant neutralising antibody responses to live SARS-CoV-2, with GMTs of 19?5 (95% CI 16?8-22?7) and 18?3 (14?4-23?3) in participants receiving 1 ? 10[SUP]11[/SUP] and 5 ? 10[SUP]10[/SUP] viral particles, respectively. Specific interferon γ enzyme-linked immunospot assay responses post vaccination were observed in 227 (90%, 95% CI 85-93) of 253 and 113 (88%, 81-92) of 129 participants in the 1 ? 10[SUP]11[/SUP] and 5 ? 10[SUP]10[/SUP] viral particles dose groups, respectively. Solicited adverse reactions were reported by 183 (72%) of 253 and 96 (74%) of 129 participants in the 1 ? 10[SUP]11[/SUP] and 5 ? 10[SUP]10[/SUP] viral particles dose groups, respectively. Severe adverse reactions were reported by 24 (9%) participants in the 1 ? 10[SUP]11[/SUP] viral particles dose group and one (1%) participant in the 5 ? 10[SUP]10[/SUP] viral particles dose group. No serious adverse reactions were documented.
Interpretation: The Ad5-vectored COVID-19 vaccine at 5 ? 10[SUP]10[/SUP] viral particles is safe, and induced significant immune responses in the majority of recipients after a single immunisation.
Funding: National Key R&D Programme of China, National Science and Technology Major Project, and CanSino Biologics.
. 2020 Jul 20;S0140-6736(20)31605-6.
doi: 10.1016/S0140-6736(20)31605-6. Online ahead of print.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Feng-Cai Zhu[SUP] 1 [/SUP], Xu-Hua Guan[SUP] 2 [/SUP], Yu-Hua Li[SUP] 3 [/SUP], Jian-Ying Huang[SUP] 4 [/SUP], Tao Jiang[SUP] 5 [/SUP], Li-Hua Hou[SUP] 6 [/SUP], Jing-Xin Li[SUP] 7 [/SUP], Bei-Fang Yang[SUP] 2 [/SUP], Ling Wang[SUP] 3 [/SUP], Wen-Juan Wang[SUP] 7 [/SUP], Shi-Po Wu[SUP] 6 [/SUP], Zhao Wang[SUP] 2 [/SUP], Xiao-Hong Wu[SUP] 3 [/SUP], Jun-Jie Xu[SUP] 6 [/SUP], Zhe Zhang[SUP] 6 [/SUP], Si-Yue Jia[SUP] 7 [/SUP], Bu-Sen Wang[SUP] 6 [/SUP], Yi Hu[SUP] 5 [/SUP], Jing-Jing Liu[SUP] 3 [/SUP], Jun Zhang[SUP] 6 [/SUP], Xiao-Ai Qian[SUP] 2 [/SUP], Qiong Li[SUP] 2 [/SUP], Hong-Xing Pan[SUP] 7 [/SUP], Hu-Dachuan Jiang[SUP] 7 [/SUP], Peng Deng[SUP] 2 [/SUP], Jin-Bo Gou[SUP] 8 [/SUP], Xue-Wen Wang[SUP] 9 [/SUP], Xing-Huan Wang[SUP] 10 [/SUP], Wei Chen[SUP] 11 [/SUP]
Affiliations
- PMID: 32702299
- DOI: 10.1016/S0140-6736(20)31605-6
Abstract
Background: This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study.
Methods: This randomised, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan, China. Healthy adults aged 18 years or older, who were HIV-negative and previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-free, were eligible to participate and were randomly assigned to receive the vaccine at a dose of 1 ? 10[SUP]11[/SUP] viral particles per mL or 5 ? 10[SUP]10[/SUP] viral particles per mL, or placebo. Investigators allocated participants at a ratio of 2:1:1 to receive a single injection intramuscularly in the arm. The randomisation list (block size 4) was generated by an independent statistician. Participants, investigators, and staff undertaking laboratory analyses were masked to group allocation. The primary endpoints for immunogenicity were the geometric mean titres (GMTs) of specific ELISA antibody responses to the receptor binding domain (RBD) and neutralising antibody responses at day 28. The primary endpoint for safety evaluation was the incidence of adverse reactions within 14 days. All recruited participants who received at least one dose were included in the primary and safety analyses. This study is registered with ClinicalTrials.gov, NCT04341389.
Findings: 603 volunteers were recruited and screened for eligibility between April 11 and 16, 2020. 508 eligible participants (50% male; mean age 39?7 years, SD 12?5) consented to participate in the trial and were randomly assigned to receive the vaccine (1 ? 10[SUP]11[/SUP] viral particles n=253; 5 ? 10[SUP]10[/SUP] viral particles n=129) or placebo (n=126). In the 1 ? 10[SUP]11[/SUP] and 5 ? 10[SUP]10[/SUP] viral particles dose groups, the RBD-specific ELISA antibodies peaked at 656?5 (95% CI 575?2-749?2) and 571?0 (467?6-697?3), with seroconversion rates at 96% (95% CI 93-98) and 97% (92-99), respectively, at day 28. Both doses of the vaccine induced significant neutralising antibody responses to live SARS-CoV-2, with GMTs of 19?5 (95% CI 16?8-22?7) and 18?3 (14?4-23?3) in participants receiving 1 ? 10[SUP]11[/SUP] and 5 ? 10[SUP]10[/SUP] viral particles, respectively. Specific interferon γ enzyme-linked immunospot assay responses post vaccination were observed in 227 (90%, 95% CI 85-93) of 253 and 113 (88%, 81-92) of 129 participants in the 1 ? 10[SUP]11[/SUP] and 5 ? 10[SUP]10[/SUP] viral particles dose groups, respectively. Solicited adverse reactions were reported by 183 (72%) of 253 and 96 (74%) of 129 participants in the 1 ? 10[SUP]11[/SUP] and 5 ? 10[SUP]10[/SUP] viral particles dose groups, respectively. Severe adverse reactions were reported by 24 (9%) participants in the 1 ? 10[SUP]11[/SUP] viral particles dose group and one (1%) participant in the 5 ? 10[SUP]10[/SUP] viral particles dose group. No serious adverse reactions were documented.
Interpretation: The Ad5-vectored COVID-19 vaccine at 5 ? 10[SUP]10[/SUP] viral particles is safe, and induced significant immune responses in the majority of recipients after a single immunisation.
Funding: National Key R&D Programme of China, National Science and Technology Major Project, and CanSino Biologics.